Q-omics provides the consensus-scored WDR7 profile across patient tissues and cancer cell-line models. WDR7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WDR7 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, WDR7 protein abundance shows 32,168 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where WDR7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR7 survival associations across molecular data types. WDR7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR7 RNA expression–survival associations across cancer types. High WDR7 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, SCLC, PAAD, ACC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WDR7 RNA expression.
This table summarizes WDR7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR7 shows lower tumor expression in COAD, THCA, UCEC, READ, BLCA and LUSC. The COAD box plot shows higher WDR7 RNA expression in normal versus tumor tissue (log2 FC = −0.841, t-test p < 0.001).
This table shows molecular features associated with WDR7 in patient tissues and cancer cell lines. In patient samples, WDR7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
